Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: END044
MIFTS: 63

Endometriosis

Categories: Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Endometriosis

About this section

MalaCards integrated aliases for Endometriosis:

Name: Endometriosis 12 74 36 29 54 6 42 43 15 62 17 71 32

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:289
KEGG 36 H01639
ICD9CM 34 617
MeSH 43 D004715
NCIt 49 C3014
SNOMED-CT 67 396224008
ICD10 32 N80 N80.9
UMLS 71 C0014175
Sources

Summaries for Endometriosis

About this section
MedlinePlus : 42 What is endometriosis? The uterus, or womb, is the place where a baby grows when a woman is pregnant. It is lined with tissue (endometrium). Endometriosis is a disease in which tissue that is similar to the lining of the uterus grows in other places in your body. These patches of tissue are called "implants," "nodules," or "lesions." They are most often found On or under the ovaries On the fallopian tubes, which carry egg cells from the ovaries to the uterus Behind the uterus On the tissues that hold the uterus in place On the bowels or bladder In rare cases, the tissue may grow on your lungs or in other parts of your body. What causes endometriosis? The cause of endometriosis is unknown. Who is at risk for endometriosis? Endometriosis is most commonly diagnosed in women in their 30s and 40s. But it can affect any female who menstruates. Certain factors can raise or lower your risk of getting it. You are at higher risk if You have a mother, sister, or daughter with endometriosis Your period started before age 11 Your monthly cycles are short (less than 27 days) Your menstrual cycles are heavy and last more than 7 days You have a lower risk if You have been pregnant before Your periods started late in adolescence You regularly exercise more than 4 hours a week You have a low amount of body fat What are the symptoms of endometriosis? The main symptoms of endometriosis are Pelvic pain, which affects about 75 percent of women with endometriosis. It often happens during your period. Infertility, which affects up to half of all women with endometriosis Other possible symptoms include Painful menstrual cramps, which may get worse over time Pain during or after sex Pain in the intestine or lower abdomen Pain with bowel movements or urination, usually during your period Heavy periods Spotting or bleeding between periods Digestive or gastrointestinal symptoms Fatigue or lack of energy How is endometriosis diagnosed? Surgery is the only way to know for sure that you have endometriosis. First, however, your health care provider will ask about your symptoms and medical history. You will have a pelvic exam and may have some imaging tests. The surgery to diagnose endometriosis is a laparoscopy. This is a type of surgery that uses a laparoscope, a thin tube with a camera and light. The surgeon inserts the laparoscope through a small cut in the skin. Your provider can make a diagnosis based on how the patches of endometriosis look. He or she may also do a biopsy to get a tissue sample. What are the treatments for endometriosis? There is no cure for endometriosis, but there are treatments for the symptoms. Your health care provider will work with you to decide which treatments would be best for you. Treatments for endometriosis pain include Pain relievers, including nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen and a prescription medicine specifically for endometriosis. Providers may sometimes prescribe opioids for severe pain. Hormone therapy, including birth control pills, progestin therapy, and gonadotropin-releasing hormone (GnRH) agonists. GnRH agonists cause a temporary menopause, but also help control the growth of endometriosis. Surgical treatments for severe pain, including procedures to remove the endometriosis patches or cut some nerves in the pelvis. The surgery may be a laparoscopy or major surgery. The pain may come back within a few years after surgery. If the pain is very severe, a hysterectomy may be an option. This is a surgery to remove the uterus. Sometimes providers also remove the ovaries and fallopian tubes as part of a hysterectomy. Treatments for infertility caused by endometriosis include Laparoscopy to remove the endometriosis patches In vitro fertilization NIH: National Institute of Child Health and Human Development

MalaCards based summary : Endometriosis is related to mayer-rokitansky-kuster-hauser syndrome and in situ carcinoma, and has symptoms including pelvic pain and pain and other symptoms associated with female genital organs. An important gene associated with Endometriosis is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Goserelin and Desogestrel have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and colon.

Disease Ontology : 12 A female reproductive system disease characterized by the growth of endometrial tissue outside the uterine body.

KEGG : 36 Endometriosis is defined as the growth of the endometrial glands and stroma at extra-uterine sites, which are most commonly implanted over and under visceral and peritoneal surfaces within the female pelvis but which can also be found in the connective tissue in the pelvis areas and, more rarely, in any anatomic district. It is a major cause of infertility, dysmenorrhea, dyspareunia, and chronic pelvic pain, mediated by marked pelvic inflammation. While retrograde menstruation is the most widely accepted cause, its pathogenesis and natural course are not fully understood. Endometriosis is known to be a estrogen-dependent disease, manifests during reproductive years.

PubMed Health : 62 About endometriosis: Endometriosis is one of the most common medical conditions affecting the abdomen (lower belly) in women. In endometriosis, the kind of tissue that normally lines the inside of the womb (endometrial tissue) also grows outside of it. The medical term for endometrial tissue that has grown outside of the womb is “endometrial implants.” Some women have them without knowing it. But other women experience endometriosis as a chronic disease that causes severe pain and fertility problems. It often takes years for endometriosis to be diagnosed as the cause of these problems. Until the diagnosis is made, many women try to cope with their pain somehow. They believe that the pain – even really bad pain – is a normal part of their menstrual period. There is currently no cure for endometriosis. But there are many things that can be done to relieve the symptoms. If treatment is adapted to suit women’s personal circumstances and the severity of their endometriosis, many can cope quite well with the disease. Like with other chronic conditions, it's important to get to know your own body and how it reacts, in order to find ways to manage the symptoms. Getting hold of good information and consulting experienced, supportive doctors can help.

Wikipedia : 74 Endometriosis is a condition in which cells similar to those in the endometrium, the layer of tissue... more...

Sources

Related Diseases for Endometriosis

About this section

Diseases in the Endometriosis family:

Endometriosis 1

Diseases related to Endometriosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 757)
# Related Disease Score Top Affiliating Genes
1 mayer-rokitansky-kuster-hauser syndrome 30.7 WNT4 H19
2 in situ carcinoma 30.5 MIR143 MIR142 MIR126
3 uterine anomalies 30.4 MIR99A MIR34C MIR29C MIR200B MIR200A MIR145
4 coronary heart disease 1 30.3 MIR145 MIR126 H19 CDKN2B-AS1
5 endometrial cancer 30.2 MIR200B MIR200A MIR145 MIR142 MIR141 H19
6 renal hypertension 29.7 MIR200B MIR200A MIR141
7 disease of mental health 29.6 MIR223 MIR142 MIR126 MIR125A
8 intestinal benign neoplasm 29.6 MIR20A MIR145 MIR143 MIR142
9 rectum cancer 29.1 MIR99A MIR424 MIR20A MIR200A MIR145 MIR143
10 melanoma 29.1 MIR34C MIR200B MIR200A MIR141 MIR100 H19
11 multiple sclerosis 29.1 MIR223 MIR20A MIR145 MIR142 MIR125A
12 leukemia, acute lymphoblastic 29.0 MIR424 MIR223 MIR142 MIR126 MIR125A CDKN2B-AS1
13 kidney cancer 28.9 MIR424 MIR29C MIR20A MIR200B MIR141 MIR126
14 lymphoma, non-hodgkin, familial 28.9 MIR424 MIR20A MIR200B MIR143 MIR142 MIR126
15 breast disease 28.8 MIR20A MIR200B MIR200A MIR145 MIR143 MIR142
16 ovarian disease 28.7 MIR34C MIR223 MIR200B MIR200A MIR145 MIR143
17 arteries, anomalies of 28.2 MIR29C MIR223 MIR145 MIR143 MIR142 MIR141
18 renal cell carcinoma, nonpapillary 28.2 MIR99A MIR29C MIR200A MIR145 MIR143 MIR142
19 intestinal disease 28.2 MIR99A MIR424 MIR29C MIR20A MIR200B MIR200A
20 pharynx cancer 28.1 MIR99A MIR34C MIR29C MIR145 MIR143 MIR142
21 lung cancer susceptibility 3 27.9 MIR99A MIR29C MIR200B MIR200A MIR145 MIR143
22 cervical cancer 27.9 MIR424 MIR34C MIR20A MIR200B MIR200A MIR145
23 ovarian cancer 27.5 MIR99A MIR424 MIR34C MIR29C MIR223 MIR200B
24 bladder disease 27.3 MIR99A MIR424 MIR34C MIR29C MIR200A MIR145
25 bladder cancer 27.3 MIR99A MIR29C MIR223 MIR200A MIR145 MIR143
26 prostate cancer 27.0 MIR99A MIR223 MIR20A MIR200B MIR145 MIR143
27 urinary system disease 26.4 MIR99A MIR424 MIR29C MIR223 MIR200B MIR200A
28 gastrointestinal system disease 26.3 MIR99A MIR424 MIR34C MIR29C MIR223 MIR20A
29 colorectal cancer 26.3 WNT4 MIR99A MIR424 MIR34C MIR29C MIR223
30 pancreatic cancer 26.1 MIR99A MIR424 MIR34C MIR223 MIR20A MIR200A
31 reproductive system disease 26.0 MIR99A MIR424 MIR34C MIR29C MIR223 MIR20A
32 lung cancer 25.5 MIR99A MIR424 MIR34C MIR29C MIR223 MIR20A
33 endometriosis of ovary 12.9
34 extrapelvic endometriosis 12.5
35 fallopian tube endometriosis 12.5
36 endometriosis of pelvic peritoneum 12.4
37 cervix endometriosis 12.4
38 endometriosis 1 12.4
39 endometriosis of intestine 12.3
40 endometriosis of rectovaginal septum and vagina 12.3
41 endometriosis in scar of skin 12.3
42 adenomyosis 12.2
43 catamenial pneumothorax 11.8
44 adenosarcoma 11.7
45 chronic pain 11.6
46 benign multicystic peritoneal mesothelioma 11.2
47 infertility 11.2
48 ovarian cyst 10.8
49 pneumothorax 10.7
50 constipation 10.7

Comorbidity relations with Endometriosis via Phenotypic Disease Network (PDN):


Myofibroma

Graphical network of the top 20 diseases related to Endometriosis:



Diseases related to Endometriosis
Sources

Symptoms & Phenotypes for Endometriosis

About this section

UMLS symptoms related to Endometriosis:


pelvic pain, pain and other symptoms associated with female genital organs
Sources

Drugs & Therapeutics for Endometriosis

About this section

PubMed Health treatment related to Endometriosis: 62

There is currently no “cure” for endometriosis – in other words, there are no treatments that can fight what is causing it. But various treatments can help relieve the symptoms, temporarily or permanently. The medication options include painkillers, hormonal contraception and stronger hormone therapy . Painkillers only relieve the symptoms, whereas hormone-based treatments slow down the growth of endometrial implants . Surgery is also an option. The aim of surgery for endometriosis is usually to remove as many endometrial implants as possible. Sometimes surgery is even necessary – for instance, if endometriosis is affecting bowel or bladder function.

Drugs for Endometriosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4 65807-02-5 5311128 47725
2
Desogestrel Approved Phase 4 54024-22-5 40973
3
Dienogest Approved Phase 4 65928-58-7
4
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
5
Danazol Approved Phase 4 17230-88-5 28417
6
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
7
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Drospirenone Approved Phase 4 67392-87-4 68873
10
Sage Approved Phase 4
11
Opium Approved, Illicit Phase 4 8008-60-4
12
Glycerol Approved, Investigational Phase 4 56-81-5 753
13
Belladonna Approved, Experimental Phase 4
14
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
15
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
16
Misoprostol Approved Phase 4 59122-46-2 5282381
17
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
18
Polyestradiol phosphate Approved Phase 4 28014-46-2
19
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
20
Calcium carbonate Approved, Investigational Phase 4 471-34-1
21
Tibolone Approved, Investigational Phase 4 5630-53-5
22
Menotropins Approved Phase 4 61489-71-2, 9002-68-0 5360545
23
Buserelin Approved, Investigational Phase 4 57982-77-1
24
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
25
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
26
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
27
Norgestrel Approved Phase 4 6533-00-2 13109
28
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
29
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
31
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
32
Norepinephrine Approved Phase 4 51-41-2 439260
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
35
St. John's Wort Approved, Investigational, Nutraceutical Phase 4 84082-80-4
36
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
37 Gallopamil Investigational Phase 4 16662-47-8
38
Enclomiphene Investigational Phase 4 15690-57-0
39
Resveratrol Investigational Phase 4 501-36-0 445154
40
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
41 Adjuvants, Immunologic Phase 4
42 Viscosupplements Phase 4
43 Platelet Aggregation Inhibitors Phase 4
44 Protective Agents Phase 4
45 Estrogen Antagonists Phase 4
46 Estrogen Receptor Antagonists Phase 4
47 Aromatase Inhibitors Phase 4
48 Neuromuscular Blocking Agents Phase 4
49 Clomiphene Phase 4
50 Citrate Phase 4

Interventional clinical trials:

(show top 50) (show all 603)
# Name Status NCT ID Phase Drugs
1 Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain Unknown status NCT02213081 Phase 4 Ulipristal
2 A Randomized Study Comparing Goserelin or Expectant Management Following Laparoscopic Surgery for Advanced Endometriosis Unknown status NCT00654524 Phase 4 gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin
3 Randomised, Controlled Clinical Study With Patients With Endometriosis and the Desire to Have Children - Comparison Between Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesionbarrier Unknown status NCT02165917 Phase 4
4 A Prospective, Randomized Controlled Trial Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery Unknown status NCT02385448 Phase 4 Dienogest;Microgynon
5 Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis Unknown status NCT02237131 Phase 4 Oral contraceptives cyclic;Oral contraceptives continuous
6 Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial. Unknown status NCT00844012 Phase 4 Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy);Cyclic OC (clormadinone acetate plus ethinil-estradiol)
7 A Randomized, Double-blind, Placebo-controlled Post-marketing Study to Assess the Treatment Effect of Sanjie Analgesic Capsule in Treating Endometriosis - Associated Pain Unknown status NCT02031523 Phase 4 Sanjie analgesic capsule;placebo
8 Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest Unknown status NCT02575248 Phase 4 Dienogest 2mg;Clomiphene citrate 5 mg
9 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Unknown status NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
10 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
11 Electrosurgical Unipolar Vessel Sealing Versus Purohit Technique in Vaginal Hysterectomy . ( A Pilot Randomized Clinical Trial) Unknown status NCT03228654 Phase 4
12 Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide). Completed NCT01769781 Phase 4 anastrazole;GnRH analog alone
13 Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis Completed NCT00286351 Phase 4 Combined treatment with Arimidex and Zoladex before IVF
14 IVF Outcome in Patients With Peritoneal Endometriosis. The Impact of a Hormonal Treatment of the Endometriosis Prior to the IVF on the Pregnancy Rates. Completed NCT01682642 Phase 4 Zoladex
15 Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions. Completed NCT00625950 Phase 4
16 Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis Completed NCT02427386 Phase 4 dynamized estrogen;placebo
17 A Comparative Study, Randomized, Blinded, About the Effect of Pre-treatment With GnRH Analogues Versus Placebo in Infertile Patients With Endometriosis Undergoing in Vitro Fertilization Treatment Completed NCT01581359 Phase 4 Triptorelin acetate
18 Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF Completed NCT01779232 Phase 4 Danazol;placebo
19 Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial. Completed NCT01056042 Phase 4 intramuscular depot medroxyprogesterone acetate;ethinyl estradiol 30 micrograms, gestodene 75 micrograms
20 Effects of the Levonorgestrel-releasing Intrauterine System Compared With the Leuprolide Acetate in Patients With Endometriosis: a Randomized Trial Completed NCT02158845 Phase 4 LNG-IUS: levonorgestrel intrauterine system;GnRHa: leuprolide
21 Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis Completed NCT02480647 Phase 4 Levonorgestrel;Etonogestrel
22 Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients Completed NCT02534688 Phase 4 LNG-IUS;DMPA
23 Do Endometrial Implantation Markers Predict in Vitro Fertilization-Embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension? Completed NCT00621179 Phase 4 Leuprolide acetate in depot suspension;Leuprolide acetate;leuprolide acetate
24 The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial Completed NCT02475564 Phase 4 Placebo;Resveratrol
25 SAGE: Supplementation in Adolescent Girls With Endometriosis Completed NCT02387931 Phase 4
26 A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women Completed NCT00735852 Phase 4 Decapeptyl SR 11.25mg
27 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
28 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
29 Intra-uterine Injection of Human Chorionic Gonadotrophin Before Embryo Transfer in ICSI Completed NCT01030393 Phase 4 human chorionic gonadotrophin
30 Effects of St. John's Wort on Levonorgestrel Completed NCT00131885 Phase 4 Levonorgestrel
31 Coasting Versus Gonadotrophin-Releasing Hormone Antagonist Administration in Patients at High Risk of Ovarian Hyperstimulation Syndrome and Its Impact on the Embryos Quality and the Outcome of ICSI Completed NCT03996434 Phase 4 Gonadotropin;Antagonist
32 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial Completed NCT01262573 Phase 4
33 Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery Completed NCT02812186 Phase 4 Rocuronium
34 Which do You Think is the Best Treatment Choice in Primary Dysmenorrhea? Completed NCT03124524 Phase 4 estradiol valerate/dienogest;ethinylestradiol and drospirenone
35 The Use of Mild Stimulation Protocol in Poor Responders : a Randomized Trial Completed NCT01213147 Phase 4 clomiphene citrate;buserelin
36 Belladonna and Opium Rectal Suppository Effect on Postoperative Pain and Nausea Following Total Laparoscopic and Robotic-Assisted Hysterectomy Completed NCT03657407 Phase 4 Belladonna Opium;Glycerin Suppository
37 Estimation of Vascularization After Treatment of Deep Rectovaginal Endometriosis Node by Rectal Shaving, Using Indocyanine Green Injection. Feasibility Study Recruiting NCT03080558 Phase 4 Indocyanine green
38 Effects of Dienogest and Dienogest Plus Estradiol Valerate on Ovarian Reserve and Endometrioma Size Recruiting NCT03789123 Phase 4 Estradiol valerate/dienogest
39 The Efficacy and Safety of Xuefu Zhuyu Capsule in Treating "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome): a Randomized, Double-blind, Placebo-controlled, Adaptive Enrichment, Multicenter Controlled Trial Recruiting NCT04218487 Phase 4 Xuefu-Zhuyu Capsule;placebo
40 Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain Recruiting NCT02214550 Phase 4 microgestin 1/20
41 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
42 Bioenergetic and Metabolic Consequences of the Loss of Ovarian Function in Women - 2018 Recruiting NCT04043520 Phase 4 GnRH antagonist;Estrogen Product;Placebo estradiol;Placebo GnRH antagonist
43 Efficacy of Vaginal Misoprostol For Pain Relief During Office Hysteroscopy and Endometrial Biopsy; A Double Blind Randomized Controlled Trial Recruiting NCT03547778 Phase 4 Misoprostol 50 mcg pesssary;Placebos
44 Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and / or Adenomyosis: Randomized Prospective Study Not yet recruiting NCT04356664 Phase 4 GnRH agonist
45 Psychological Impact of Amenorrhea in Women With Endometriosis: Perspective Randomized Study Not yet recruiting NCT02393482 Phase 4 Estroprogestinic therapy (Etinil-estradiol/levonorgestre);Gonadotropin-releasing hormone agonist (Leuprorelin acetate);Add back therapy 1 (tibolone);Add back therapy 2 (calcium carbonate/colecalciferol)
46 Can Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist Withstand When Administered at Different Points in the Menstrual Cycle? Not yet recruiting NCT04060992 Phase 4 Elagolix 200 MG Oral Tablet [Orilissa]
47 Trans-vaginal Aspiration With or Without Injection of Surgicel for Treatment of Small Ovarian Endometrioma Before ICSI Cycles. A Randomized Controlled Trial Not yet recruiting NCT03784404 Phase 4 Intracytoplasmic sperm injection
48 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Not yet recruiting NCT03946722 Phase 4 GnRH analogue downregulation
49 The Effectiveness and Safety of the Early Follicular Phase Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation: a Randomized, Paralleled, Controlled, Multicenter Trial Not yet recruiting NCT03809221 Phase 4 Triptorelin acetate
50 Comparison of Embryo Transfer With and Without PGS for the Indication of Advanced Reproductive Age (37-42) in Patients Undergoing ART Suspended NCT00646893 Phase 4

Search NIH Clinical Center for Endometriosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


17-alpha-Hydroxyprogesterone
Danazol
Desogestrel
Ethynodiol Diacetate
Goserelin Acetate
hydroxyprogesterone caproate (USP)
Leuprolide
Leuprolide Acetate
Nafarelin
Nafarelin Acetate
Norethindrone
norethindrone acetate

Cochrane evidence based reviews: endometriosis

Sources

Genetic Tests for Endometriosis

About this section

Genetic tests related to Endometriosis:

# Genetic test Affiliating Genes
1 Endometriosis 29
Sources

Anatomical Context for Endometriosis

About this section

MalaCards organs/tissues related to Endometriosis:

40
Uterus, Ovary, Colon, Endothelial, Bone, Appendix, Testes
Sources

Publications for Endometriosis

About this section

Articles related to Endometriosis:

(show top 50) (show all 22762)
# Title Authors PMID Year
1
Analysis of factors related to fertility after endometriosis combined with infertility laparoscopic surgery. 61 42
32481283 2020
2
Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist. 42 61
32366386 2020
3
Malignant risk of pelvic mass after hysterectomy for adenomyosis or endometriosis. 42 61
32282727 2020
4
MicroRNA-regulated pathways associated with endometriosis. 61 46
19074548 2009
5
Letrozole and norethisterone acetate in colorectal endometriosis. 61 54
20227163 2010
6
Interleukin-4 induces expression of eotaxin in endometriotic stromal cells. 54 61
19338989 2010
7
Endometriotic epithelial cells induce MMPs expression in endometrial stromal cells via an NFkappaB-dependent pathway. 61 54
19903119 2010
8
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 54 61
19342032 2010
9
Matrix metalloproteinase messenger RNA expression in human endometriosis grafts cultured on a chicken chorioallantoic membrane. 61 54
19345347 2010
10
Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. 61 54
19324337 2010
11
Steroidogenic factor-1 expression in ovarian endometriosis. 54 61
19875956 2010
12
[Aromatase and endometriosis: myth or reality]. 54 61
20430669 2010
13
[Treatment of endometriosis by aromatase inhibitors: efficacy and side effects]. 61 54
20430665 2010
14
The roles of thioredoxin and thioredoxin-binding protein-2 in endometriosis. 54 61
20172870 2010
15
Immunohistochemical detection of steroid receptor cofactors in ovarian endometriosis: involvement of down-regulated SRC-1 expression in the limited growth activity of the endometriotic epithelium. 61 54
20155281 2010
16
[Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in human and nude mouse ectopic endometrium and the effect of estrogen and progestin on their expression]. 61 54
20423842 2010
17
Proteomic analysis of endometrium from fertile and infertile patients suggests a role for apolipoprotein A-I in embryo implantation failure and endometriosis. 54 61
20008415 2010
18
Estrogen and progesterone receptors in smooth muscle component of deep infiltrating endometriosis. 61 54
19217090 2010
19
17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. 54 61
19932734 2010
20
Effect of human seminal fluid on the growth of endometrial cells of women with endometriosis. 61 54
20092935 2010
21
Expression of macrophage migration inhibitory factor in human endometriosis: relation to disease stage, menstrual cycle and infertility. 54 61
20492386 2010
22
Analysis of matrix metalloproteinase-7 expression in eutopic and ectopic endometrium samples from patients with different forms of endometriosis. 54 61
20007614 2010
23
Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression. 54 61
20074813 2010
24
Regulation of monocyte chemotactic protein-1 expression in human endometrial endothelial cells by sex steroids: a potential mechanism for leukocyte recruitment in endometriosis. 54 61
19933497 2010
25
Effect of vascular endothelial growth factor and interleukin-1beta on apoptosis in endometrial cell cultures from patients with endometriosis and controls. 61 54
20137818 2010
26
Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis. 54 61
20023295 2010
27
Non-invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. 54 61
20007161 2010
28
Influence of peritoneal fluid on the expression of angiogenic and proteolytic factors in cultures of endometrial cells from women with endometriosis. 61 54
19945964 2010
29
Lipopolysaccharide promoted proliferation and invasion of endometriotic stromal cells via induction of cyclooxygenase-2 expression. 54 61
19647233 2010
30
17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. 61 54
20108182 2010
31
Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. 61 54
20104427 2010
32
Molecular mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions. 61 54
20104430 2010
33
Peritoneal vascular density assessment using narrow-band imaging and vascular analysis software, and cytokine analysis in women with and without endometriosis. 54 61
19892605 2010
34
Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. 54 61
20085636 2010
35
Association of interleukin 1beta gene (+3953) polymorphism and severity of endometriosis in Turkish women. 54 61
19757173 2010
36
Expression of cyclooxygenase-2 in eutopic endometrium and ovarian endometriotic tissue in women with severe endometriosis. 61 54
20068324 2010
37
Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. 61 54
19898423 2010
38
Haptoglobin expression in endometrioid adenocarcinoma of the uterus. 61 54
19801537 2010
39
Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. 61 54
19726448 2009
40
HOXA-10 expression in the mid-secretory endometrium of infertile patients with either endometriosis, uterine fibromas or unexplained infertility. 61 54
19736237 2009
41
Cyclooxygenase-2 expression, Ki-67 labeling index, and perifocal neovascularization in endometriotic lesions. 61 54
19917472 2009
42
Fenofibrate causes regression of endometriotic implants: a rat model. 54 61
19580963 2009
43
Effect of Yikun Neiyi Wan on the expression of aromatase P450, COX-2, and ER related receptor in endometrial cells in vitro from patients with endometriosis. 54 61
20112494 2009
44
Elevated ghrelin levels in the peritoneal fluid of patients with endometriosis: associations with vascular endothelial growth factor (VEGF) and inflammatory cytokines. 54 61
18976754 2009
45
Electrodermal measures of Jing-Well points and their clinical relevance in endometriosis-related chronic pelvic pain. 54 61
19958132 2009
46
Hepatocyte nuclear factor-1beta(HNF-1beta) in human urogenital organs: its expression and role in embryogenesis and tumorigenesis. 54 61
19760597 2009
47
Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. 61 54
20512287 2009
48
Recent patent trends in the field of progesterone receptor agonists and modulators. 61 54
19785507 2009
49
Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium. 54 61
19661125 2009
50
Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis. 61 54
19661147 2009
Sources

Variations for Endometriosis

About this section

ClinVar genetic disease variations for Endometriosis:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FAM163A t(1;5)(q25;q12)Translocation Uncertain significance 810664 1:179785309-179785316
2 t(3;10)(q22;q25.3)Translocation Uncertain significance 810665 10:130029678-130029684
Sources

Expression for Endometriosis

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Endometriosis patients vs. healthy controls: 35 (show top 50) (show all 83)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PTGIS prostaglandin I2 (prostacyclin) synthase Uterus + 5.41 0.000
2 MYH11 myosin, heavy chain 11, smooth muscle Uterus + 4.87 0.001
3 ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide Uterus + 4.81 0.000
4 CNN1 calponin 1, basic, smooth muscle Uterus + 4.71 0.000
5 TAGLN transgelin Uterus + 4.63 0.000
6 PAEP progestagen-associated endometrial protein Uterus + 4.63 0.013
7 PRELP proline/arginine-rich end leucine-rich repeat protein Uterus + 4.59 0.000
8 C7 complement component 7 Uterus + 4.54 0.003
9 ACTG2 actin, gamma 2, smooth muscle, enteric Uterus + 4.48 0.003
10 TCF21 transcription factor 21 Uterus + 4.45 0.000
11 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) Uterus - 4.42 0.001
12 WISP2 WNT1 inducible signaling pathway protein 2 Uterus + 4.11 0.001
13 AQP1 aquaporin 1 (Colton blood group) Uterus + 4.10 0.000
14 EHF ets homologous factor Uterus - 4.10 0.000
15 FOS FBJ murine osteosarcoma viral oncogene homolog Uterus + 4.09 0.000
16 FOSB FBJ murine osteosarcoma viral oncogene homolog B Uterus + 4.07 0.000
17 SLC3A1 solute carrier family 3 (amino acid transporter heavy chain), member 1 Uterus - 4.05 0.010
18 LMNB1 lamin B1 Uterus - 4.05 0.000
19 SLC26A4 solute carrier family 26 (anion exchanger), member 4 Uterus - 3.99 0.000
20 DPT dermatopontin Uterus + 3.98 0.000
21 DES desmin Uterus + 3.97 0.001
22 KCNMB1 potassium channel subfamily M regulatory beta subunit 1 Uterus + 3.96 0.001
23 GATA6 GATA binding protein 6 Uterus + 3.89 0.004
24 FZD7 frizzled class receptor 7 Uterus + 3.89 0.000
25 LEFTY2 left-right determination factor 2 Uterus + 3.88 0.001
26 SLC26A4 solute carrier family 26 (anion exchanger), member 4 Uterus - 3.87 0.001
27 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) Uterus - 3.86 0.001
28 ACKR1 atypical chemokine receptor 1 (Duffy blood group) Uterus + 3.84 0.001
29 EFHC2 EF-hand domain (C-terminal) containing 2 Uterus - 3.75 0.000
30 PDLIM3 PDZ and LIM domain 3 Uterus + 3.72 0.001
31 GPC3 glypican 3 Uterus + 3.71 0.003
32 IL20RA interleukin 20 receptor, alpha Uterus - 3.70 0.000
33 MYL9 myosin, light chain 9, regulatory Uterus + 3.70 0.001
34 VNN1 vanin 1 Uterus - 3.69 0.008
35 CTSZ cathepsin Z Uterus - 3.68 0.000
36 EHF ets homologous factor Uterus - 3.67 0.000
37 LMNB1 lamin B1 Uterus - 3.61 0.000
38 CLU clusterin Uterus + 3.58 0.002
39 ACTA2 actin, alpha 2, smooth muscle, aorta Uterus + 3.57 0.000
40 TCEAL2 transcription elongation factor A (SII)-like 2 Uterus + 3.53 0.001
41 LMOD1 leiomodin 1 (smooth muscle) Uterus + 3.52 0.003
42 LMO3 LIM domain only 3 (rhombotin-like 2) Uterus + 3.51 0.002
43 TPD52 tumor protein D52 Uterus - 3.50 0.000
44 SYNPO synaptopodin Uterus + 3.48 0.001
45 KLF2 Kruppel-like factor 2 Uterus + 3.44 0.000
46 AOC3 amine oxidase, copper containing 3 Uterus + 3.44 0.003
47 KCNK3 potassium channel, two pore domain subfamily K, member 3 Uterus + 3.44 0.007
48 ZBBX zinc finger, B-box domain containing Uterus - 3.43 0.001
49 FMO1 flavin containing monooxygenase 1 Uterus + 3.43 0.000
50 ZBBX zinc finger, B-box domain containing Uterus - 3.42 0.002
Search GEO for disease gene expression data for Endometriosis.
Sources

Pathways for Endometriosis

About this section

Pathways related to Endometriosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.93 MIR99A MIR34C MIR29C MIR223 MIR20A MIR200B
2
miRNAs involved in DNA damage response 1
11.03 MIR34C MIR145 MIR100
3
miRNA targets in ECM and membrane receptors 1
10.77 MIR200B MIR200A MIR141
Sources

GO Terms for Endometriosis

About this section

Cellular components related to Endometriosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.43 MIR99A MIR29C MIR20A MIR126 MIR125A MIR100
2 extracellular space GO:0005615 9.4 WNT4 MIR99A MIR424 MIR29C MIR223 MIR20A

Biological processes related to Endometriosis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.73 WNT4 MIR29C MIR20A MIR200B MIR125A CDKN2B-AS1
2 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.7 MIR424 MIR29C MIR20A
3 positive regulation of blood vessel endothelial cell migration GO:0043536 9.69 MIR200A MIR143 MIR126
4 miRNA mediated inhibition of translation GO:0035278 9.67 MIR20A MIR200B MIR145 MIR100
5 negative regulation of inflammatory response GO:0050728 9.63 MIR223 MIR20A MIR145 MIR142 MIR141 MIR126
6 negative regulation of protein kinase B signaling GO:0051898 9.62 MIR34C MIR29C MIR20A MIR145
7 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.61 MIR20A MIR143
8 negative regulation of vascular endothelial cell proliferation GO:1905563 9.61 MIR424 MIR29C MIR126
9 negative regulation of fibroblast growth factor receptor signaling pathway GO:0040037 9.6 WNT4 MIR424
10 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.59 MIR424 MIR223
11 regulation of smooth muscle contraction GO:0006940 9.58 MIR145 MIR143
12 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.58 MIR99A MIR125A
13 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.57 MIR34C MIR20A
14 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.56 MIR141 MIR125A
15 angiotensin-activated signaling pathway GO:0038166 9.55 MIR145 MIR143
16 negative regulation of STAT cascade GO:1904893 9.54 MIR99A MIR125A
17 gene silencing by miRNA GO:0035195 9.53 MIR99A MIR424 MIR34C MIR29C MIR223 MIR20A
18 aorta smooth muscle tissue morphogenesis GO:0060414 9.49 MIR145 MIR143
19 regulation of phenotypic switching GO:1900239 9.48 MIR145 MIR143
20 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.46 MIR20A MIR143
21 negative regulation of angiogenesis GO:0016525 9.43 MIR424 MIR29C MIR200B MIR145 MIR143 MIR125A
22 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.4 MIR145 MIR143

Molecular functions related to Endometriosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR99A MIR424 MIR29C MIR223 MIR20A MIR200B
2 mRNA 3'-UTR binding GO:0003730 9.33 MIR20A MIR200B MIR125A
3 RNA polymerase II complex binding GO:0000993 9.26 MIR20A MIR145 MIR126 MIR125A
Sources

Sources for Endometriosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....